Advances and development in transdermal drug delivery system-A review
DOI:
https://doi.org/10.7439/ijap.v6i2.3862Abstract
It is one of the best pharmaceutical dosage forms for those patients, they cannot take medicaments orally. Transdermal drug delivery system (TDDS) established itself as an integral part of novel drug delivery systems (NDDS). On the application of Transdermal patches, the delivery of the drug across dermis gives the systemic effect. TDDS is costly alternative to conventional formulation. It is also important due to its unique advantage. Controlled absorption, more uniform plasma levels, improved bioavailability, reduced side effects, painless and simple application and flexibility of terminating drug administration by simply removing the patch from the skin are some of the potential advantages of transdermal drug delivery. Development of controlled release transdermal dosage form is a complex process involving extensive efforts. This review article describes the methods of preparation of different types of transdermal patches. In addition, the various methods of evaluation of transdermal dosage form and Advance Development in TDDS have also been reviewed.Downloads
References
Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems, Pharmaceutical Technology 2002, 62-78.
Guy RH. Current status and future prospects of transdermal drug delivery, Pharm Res 1996, 13, 1765-1769.
Guy RH, Hadgraft J, Bucks DA. Transdermal drug delivery and cutaneous metabolism, Xenobiotica 1987, 7, 325-343.
Chein YW. Transdermal Controlled Systemic Medication. New York and Basel, Marcel Dekker Inc. 1987; 159
Weiner E, Victor A, Johansson ED. Plasma levels of d-Norgestel after oral administration. Contraception 1976, 14: 563-570.
Keith AD, Polymer matrix consideration for Transdermal Devices. Drug Dev Ind Pharm. 1983, 9: 605-625
Karim A. Transdermal absorption: a unique opportunity for constant delivery of nitroglycerin. Drug Dev Ind Pharm. 1983, 9: 671.
Helier J, Trescony PV. Controlled drug release by polymer dissolution II, Enzyme mediated delivery device. J. Pharm. Sci. 1979, 68: 919.
Dermatological and Transdermal Formulations. Marcel Dekker, Inc. New York 2002
Bronaugh RL, Maibach HI. Percutaneous Absorption: Drugs - Cosmetics - Mechanisms - Methodology (Drugs and the Pharmaceutical Sciences). Informa Healthcare; 4th Ed., 2005.
Smith EW, Maibach HI. Penetration percutaneous enhancers. Taylor and Francis, 2nd Ed, 2006.
Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E. Human stratum corneum lipids: characterization and regional differences. J Lipid Res 1983; 24: 120-30.
Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991; 24: 1-26. [PubMed]
Elias PM, Tsai JC, Menon GK. Skin barrier, percutaneous drug delivery and pharmacokinetics. Dermatology, 2003. Chap 125, p 1235-52.Mosby, editor.
Elias PM, Feingold KR, Menon JK. The stratum corneum, two compartments model and its functional implication. In Basel, Karger Shroot B, Shaefer H, editors. Skin Pharmacokinetics 1987. Vol.1. p 1-9.
Surber C, Davis AF. Bioavailability and Bioequivalence of Dermatological Formulations p401-498. in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
Roberts MS, Cross SE, Pellett MA. Skin transport p 89-195 in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
Menon GK, Elias PM. Morphologic basis for a pore-pathway in mammalian stratum corneum. Skin Pharmacol 1997; 10:235-46. [PubMed]
Watkinson AC, Brain KR. Basic mathematical principles in skin permeation p 61-88: in Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York.
Franz TJ. Kinetics of cutaneous drug penetration. Int J Dermatol 1983; 499-505. [PubMed]
Franz TJ. Pharmacokinetics and skin in: Skin barrier, percutaneous drug delivery and pharmacokinetics. p 1969-78 in Dermatology,vol II. Mosby, 2003.
Orecchia G, Sangalli ME, Gazzaniga A, et al. Topical photochemotherapy of vitiligo with a new khellin formulation: preliminary clinical results. J Dermatol Treat 1998; 9: 65-9.
Roberts M, Cross SE, Pellett MA. Skin transport in Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002.
Middleton JD. The mechanism of water binding in stratum corneum. Br J Dermatol 1968; 80:437-50
Horii I, Nakajama Y, Obate Ml. Stratum corneum hydration and aminoacids contant in xerotic skin. Br J Dermatol Res 1989; 121: 588-64.
Imokawa G, Kuno H, Kawai M. Stratum corneum lipids serve as bound-water modulator. J Invest Dermatol 1991; 96: 845-51. [PubMed]
Mauro T, Hollerann WM, Grayson S, Gao WN, Man MQ, Kriehuber E, et al. Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. Arch Dermatol Res 1998; 290: 215-22. [PubMed]
Rougier A, Lotte C, Corcuff TP. Relationship between skin permeability and cornecyte size according to anatomic site, age and sex in man. J Soc Cosmet Chem 1988; 39: 15-21. [PubMed]
Berardesca E, Maibach HI. Racial differences in skin pathophysiology. J Am Acad Dermatol 1996; 34: 667-72. [PubMed]
Menon GK, Elias PM, Feingold KR. Integrity of the permeability barrier is crucial for manteinance of the epidermal calcium gradient. Br J Dermatol 1994; 130: 139-47.
Surber C, Davis AF. Bioavailability and Bioequivalence of Dermatological Formulations p401-498. in: Dermatological and Transdermal Formulations.vol 119. Marcel Dekker, Inc. New York 2002. [PubMed]
Hauck WW. Bioequivalence studies of topical preparations: statistical considerations. Int J Dermatol 1992; 31 (suppl. 1): 29-33.
Keith AD. Polymer matrix considerations for transdermal devices, Drug Dev. Ind. Pharm 1983, 9, 605.
Baker RW, Heller J. Material selection for transdermal delivery systems; In: Hadgraft J, Guys RH, editors. Transdermal Drug Delivery: Development Issues and Research Initiatives. New York, Marcel Dekker Inc. 1989; 293-311.
Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol, Int J Pharm 2000, 204, 171-182.
Gabiga H, Cal K, Janicki S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system, Int J Pharm 2000, 199, 1-6.
Minghetti P, Cilurzo F, Casiragh A, Molla FA, Montanari L. Dermal patches for controlled release of miconazole: Influence of drug concentration on the technical characteristics, Drug Dev Ind Pharm 1999, 25, 679-684.
Tsai CJ, Hu LR, Fang JY, Lin HH. Chitosan hydrogel as a base for transdermal delivery of berberine and its evaluation in rat skin, Biol. Pharm. Bull 1999, 22, 397-401.
Bromberg L. Cross linked polyethylene glycol networks as reservoirs for protein delivery, J Apply Poly Sci 1996, 59, 459-466.
Verma PRP, Iyer SS. Transdermal delivery of propranolol using mixed grades of eudragit: Design and in vitro and in vivo evaluation, Drug Dev Ind Pharm 2000, 26, 471-476.
Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics, AAPS PharmSciTech 2007, 8(1), Article 2.
Gannu R, Vamshi Vishnu Y, Kishan V, Madhusudan Rao Y. Development of nitrendipine transdermal patches: In vitro and ex vivo characterization, Current Drug Delivery 2007, 4, 69-76.
Gale R, Spitze LA. Permeability of camphor in ethylene vinyl acetate copolymers. In proceedings: Eighth International Symposium on Controlled Release of Bioactive Materials. Minneapolis, MN, Controlled Release Society. 1981; 183.
Boretos JW, Detmer DE , Donachy JH. Segmented polyurethane: a polyether polymer II. Two year experience, J Biomed Mat Res 1971, 5, 373.
Chung SJ. Future drug delivery research in South Korea, J Controlled Release 1999, 62, 73-79.
Izumoto T, Aioi A, Uenoyana S, Kariyama K, Azuma M. Relationship between the transference of drug from a transdermal patch and physicochemical properties, Chem Pharm Bull (Tokyo) 1992, 40, 456-458.
Gordon RA, Peterson TA. Four myths about transdermal drug delivery, Drug Delivery Technology 2003, 3, 1-7.
Williams AC, Barry BW. Penetration enhancers, Advanced drug delivery reviews, 2004, 56, 603-618.
Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery, Proceedings of the national academy of sciences of the United States of America 2005,102, 4688-4693.
Thornfeldt CR. Potent penetration enhancers. US Patent 5760096 (1998).
Ning YM, Rao YF, Liang WQ. Influence of permeation enhancers on transdermal delivery of anemonia, Zhonqquo Zhong Yao Za Zhi 2007, 32, 393-396.
Budhathoki U, Thapa P. Effect of chemical enhancers on in vitro release of salbutamol sulfate from transdermal patches, Kathmandu University of Science Engineering and Technology 2005, 1(1), 1-8.
Zurdo SI, Franke P, Schaefer UF, Lehr CM. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs, J. Controlled Release 2007, 118, 196-203.
Babu RJ, Pandit JK. Effect of permeation enhancers on the transdermal delivery of bupranolol through rat skin, Drug Delivery 2005, 12, 165-169.
Oquiso T, Iwaki M, Paku T. Effect of various enhancers on transdermal penetration of indomethacin and urea and relationship between penetration parameters and enhancement factors, J Pharm Sci 1995, 84, 482-488.
Parikh DK, Tapash KG. Feasibility of transdermal delivery of fluoxetine, AAPS PharmSciTech. 2005, 6, E144-149.
Nokodchi A, Shokri J, Dashbolaghi A, Hassan Zadeh D, Ghafourian T, Barzegar Jalali M. The enhancement effect of surfactants on the penetration of lorazepam through rat skin, Int J Pharm 2003, 250, 359-369.
Mukherjee B, Kanupriya, Mahapatra S, Das S, Patra B. Sorbitan monolaurate 20 as a potential skin permeation enhancer in transdermal patches, J Applied Research 2005, 5, 96-107.
El-Kattan AF, Asbill CS, Kim N, Mickniak BB. Effect of formulation variables on the percutaneous permeation of ketoprofen from gel formulations, Drug Delivery 2000, 7, 147-153.
Huang YB, Fang JY, Hung CH, Wu PC, Tsai YH. Cyclic monoterpine extract from cardamom oil as a skin permeation enhancer for indomethacin: in vitro and in vivo studies, Biol Pharm Bull 1999, 22, 642-646.
Kaza R, Pitchaimani R. Formulation of transdermal drug delivery system: Matrix and selection of polymer- their evaluation, Current Drug Discovery Technologies 2006, 3, 279-285.
Giannakou SA, Dellas PP, Kekkas PM, Choulis NH. Development and in vitro evaluation of nimodipine transdermal formulations using factorial design, Pharm Dev Technol 1998, 3, 517-525.
Jayaaraam B, Bhaskar P. Formulation of an HPMC gel drug reservoir system with ethanol water as a solvent system and limonene as a permeation enhancer for enhancing in vitro transdermal delivery of nicorandil, J Pharmacological and Biophysiological Research 2004,17, 310-320.
Shin SC, Shin EY, Cho CY. Enhancing effects of fatty acids on piroxicam permeation through rat skins, Drug Dev Ind Pharm 2000, 26, 563-566.
Pocius AV. Adhesives. In: Howe- Grants M, Ed. Kirk-Othmer Encyclopedia of Chemical Technology. New York, Wiley-Interscience. 1991; 445-466.
Walters KA. Transdermal drug delivery systems In: Swarbick K, Boylan JC, eds. Encyclopedia of pharmaceutical technology. New York, Marcel Dekker Inc. 1997; 253-293.
Franz TJ. Transdermal Delivery. In: Kydonieus A, ed. Treatise on controlled drug delivery: Fundamentals, optimization, applications. New York, Marcel Dekker Inc. 1991; 341-421.
Tan HS, Pfister WR. Pressure sensitive adhesives for transdermal drug delivery, Pharm Sci Technol Today 1999, 2, 60-69.
Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems. Part I: Selection and formulation considerations, Med Device Technol 1990, 1, 48-55.
Godbey KJ. Improving patient comfort with nonocclusive transdermal backings, American Association of Pharmaceutical Scientists 1996, 1-2.
Foco A, Hadziabdic J, Becic F. Transdermal drug delivery systems, Med Arch 2004, 58, 230-234.
Khatun M, Ashraful Islam SM, Akter P, Abdul Quadir M, Selim Reza M. Controlled release of naproxen sodium from eudragit RS 100 transdermal film, Dhaka University J Pharm Sci 2004, 3(1-2).
Rao PR, Diwan PY. Permeability studies of cellulose acetate free films for transdermal use: Influence of plasticizers, Pharm Acta Helv 1997, 72, 47-51.
Gondaliya D, Pundarikakshudu K. Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion, AAPS PharmSciTech 2003, 4, Article3.
Baker W and Heller J.
Wiechers J. Use of chemical penetration enhancers in Transdermal drug delivery-possibilities and difficulties. Acta pharm. 1992 : 4: 123.
Yamamoto T, Katakabe k, Akiyoshi K, Kan K and Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. Diabetes res. Clin. Pract. 1990; 8: 19-22.
Al- Khamis K, Davis S.S and Hadgraft J. Microviscosity and drug release from topical gel formulations. Pharm. Res. 1986; 3: 214-217.
Anon. Transdermal delivery systems-general drug release standards. Pharmacopeial Forum, 1980; 14: 3860-3865.
Mayorga P, Puisieux F and Couarraze G. Formulation study of a Transdermal delivery system of primaquine. Int. J. pharm. 1996; 132: 71-79.
Deo M.R, Sant V.P,Parekh S.R, Khopade A.J; Proliposome-based Transdermal delivery of levonorgestrel. Jour. Biomat. Appl. 1997; 12: 77-88.
Yan-yu X, Yun- mei S, Zhi-Peng C and Qi-nerg P. Preparation of silymarin proliposomes; A new way to increase oral bioavailability of silymarin in beagle dogs. Int. pharm. 2006; 319: 162-168.
Crawford R.R and Esmerian O.K. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J. Pharm. Sci. 1997;60: 312-314.
Singh J, Tripathi K.T and SakiaT.R. Effect of penetration enhancers on the invitro transport of ephedrine through rate skin and human epidermis from matrix based Transdermal formulations. Drug Dev. Ind. Pharm. 1993; 19: 1623-1628.
Wade A, Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association; 1994: 362-366.
Rhaghuram reddy k, Muttalik S and Reddy S. Once
Shaila L, Pandey S and Udupa N. Design and evaluation of matrix type membrane controlled Transdermal drug delivery system of nicotin suitable for use in smoking cessation. Indian Journ. Pharm. Sci. 2006;68: 179-184
Aarti N, Louk A.R.M.P, Russsel.O.P and Richard H.G. Mechanism of oleic acid induced skin permeation enhancement in vivo in humans. Jour. control. Release 1995; 37: 299-306.
Lec S.T, Yac S.H, Kim S.W and Berner B. One way membrane for Transdermal drug delivery systems / system optimization. Int. J Pharm. 1991; 77: 231 -237.
Vyas S.P and Khar R.K. Targetted and controlled Drug Delivery Novel carrier system1stEd., CBS Publishers and distributors, New Delhi, 2002; 411-447.
Singh Somnath.
Prausnitz Mark. R., Mitragotri Samir., Langer Robert.
Segal Marian.
Brannon-Peppas Lisa.
Langer Robert. (2004).
Samad, Ullah A, Alam Z, Wais M I, Shams M, Mohammad S. Transdermal Drug Delivery System: Patents Reviews. Recent Pat Drug Deliv & formul. 2009, 3(2):143-52
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
